Quotes 5-day view Delayed Nasdaq
03/01/2021
03/02/2021
03/03/2021
03/04/2021
03/05/2021
Date
319.39(c)
306.46(c)
304.55(c)
289.22(c)
301.28(c)
Last
369 175
215 014
187 635
304 625
428 427
Volume
-0.19% -4.05% -0.62% -5.03% +4.17% Change
Sales 2021
898 M - -
Net income 2021
-1 324 M - -
Net cash position 2021
2 405 M - -
P/E ratio 2021
-22,4x
Yield 2021
-
Sales 2022
1 505 M - -
Net income 2022
-633 M - -
Net cash position 2022
1 728 M - -
P/E ratio 2022
-38,0x
Yield 2022
-
Capitalization
27 598 M 27 598 M -
EV / Sales 2021
28,0x
EV / Sales 2022
17,2x
Nbr of Employees
5 300
Free-Float
69,0%
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).
Notations Surperformance© of BeiGene, Ltd.
Trading Rating : Investor Rating :
All news about BEIGENE, LTD.
News in other languages on BEIGENE, LTD.
Analyst Recommendations on BEIGENE, LTD.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BEIGENE, LTD.
Short Term Mid-Term Long Term Trends Bearish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
19
Average target price
331,92 $
Last Close Price
301,28 $
Spread / Highest target
42,4%
Spread / Average Target
10,2%
Spread / Lowest Target
-47,6%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
